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Despite dramatic advances in the molecular pathogenesis of disease, translation of
basic biomedical research into safe and effective clinical applications remains a
slow, expensive, and failure-prone endeavor.
Francis S. Collins1
The global burden of stroke on patients, their relatives, health systems, and the economies
that support them is tremendous. In an unprecedented move, the World Health Organization
(WHO) and the United Nations have responded to this challenge by declaring the fight
against stroke a top priority in their drive to prevent and to control noncommunicable
diseases.2 Indeed, great progress has been made in our understanding of stroke
pathophysiology. This has led to the development of thrombolysis, a highly efficient therapy
for a subset of patients with acute ischemic stroke. We came to realize that the responses of
brain tissue to substrate deprivation are complex, and that not only neurons need to be
considered but also glial and vascular cells, as well as local or blood-derived cells of the
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immune system.3–5 We now know that ischemia triggers a multitude of endogenous
protective mechanisms in the brain which help to contain the ischemic lesion evolution and
protect the brain from further damage.6 The brain has a tremendous capacity to overcome
functional deficits, and as we begin to understand how brain plasticity works, we are
actually finding evidence for tissue repair.7 We are also beginning to appreciate the
interaction between the ischemic brain and the other organ systems, such as the immune
system,8 the cardiovascular system, or systemic metabolism, a multidirectional signaling
with tremendous impact on the outcome of patients with stroke.9 Taken together, research
during the past few decades has suggested numerous targets for therapeutic intervention to
restore perfusion, block mechanisms of damage, or induce endogenous mechanisms of
protection, intercept deleterious signaling to other organs, or to even foster plasticity or
repair to recover lost function. Treatment approaches based on this understanding have
demonstrated efficacy in a variety of preclinical models of the disease.
However, associated clinical trials have been unable to translate most of these advances into
drugs with a clear benefit in patients. Developing new drug treatments for human disease is
challenging in any field, and the number of new drugs coming to market continues to fall.
Although large numbers of novel treatment strategies are developed in laboratories each
year and show beneficial effects in animal models, very few are ultimately proven to be
effective in patients.10,11 The stroke field has been particularly affected by the failure to
translate drug efficacy in stroke from animal studies to clinical trials.12
The reasons underlying this translational roadblock13,14 are currently being discussed
intensely by stroke researchers and in industry and funding agencies worldwide. They are all
struggling to develop strategies to overcome the roadblocks impeding the development of
effective therapies. For example, the European Commission invited a group of European
stroke experts to provide research priorities for attacking this translational roadblock.15
More recently, basic and clinical stroke researchers from North America, Europe, and the
Asia-Pacific regions convened in 2 workshops (Barcelona, Spain, May 2011 and Potsdam,
Germany, May 2012). The need for international collaboration in cerebrovascular research
and therapeutics was also discussed at the meeting of the American Association for the
Advancement of Science (Boston, February 2013). Likewise, the Stroke Progress Review
Group of the National Institutes of Health (NIH)/National Institute of Neurological
Disorders and Stroke (NINDS), recently conducted a 10-year review of the state of stroke
research16 and set priorities to shape future NINDS programs and policies focusing on the
improvement of bench to beside translation and stressing the importance of research
cooperation and research networks. We wish to summarize the background for such
cooperation and outline a proposal that might be a first step toward accelerating progress in
translational stroke research.
Stroke: A Global Challenge
Worldwide >15 million strokes and 6 million stroke deaths occur per year, and 55 million
survivors are experiencing the consequences of a stroke. The costs of stroke are substantial.
After adjusting for inflation, it has been estimated that they range in the developed world
from US$266 billion to US$1038 billion each year.17 The WHO forecasts a global doubling
of these figures by 2030 as the world population ages.18 Although stroke engenders a
massive family and societal burden, we unfortunately have few effective therapies.
Thrombolysis, because of its short time window, diagnostic requirements, and
contraindications, can only benefit a small percentage of stroke patients.19 Stroke units have
proven to produce reductions in mortality, institutionalized care, or dependency, but effect
sizes and availability are limited.20 This paucity of therapeutic options persists, despite
intensive research efforts to develop new effective therapies.
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The Problem: Failure to Translate
The translation of animal model research to the stroke patient is best exemplified by the
success of reperfusion strategies. There is a wealth of large and small animal experience,
and a growing body of work on vascular processes in the central nervous system. It is clear
that the location and the extent of ischemic injury begin within the first moments of the
vascular occlusion. However, we only partially understand the exact events that ensue from
occlusion of a major brain-supplying artery, the brain’s attempts to recover from the insult,
or the complex interplay of brain, cardiovascular, and immune system before stroke hits and
in its wake. A deeper understanding of these mechanisms is a prerequisite for the
development of novel treatment strategies that benefit patients, in whom comorbidities and
age further complicate pathobiology.
In addition, there is a growing body of quantitative evidence that preclinical stroke research,
just as in other areas of biomedicine, has been confounded by quality problems and negative
publication bias.11,21,22 Our experimental paradigms are designed to show large treatment
effects, and although statistically efficient, they may be clinically less relevant. In view of
the difficulties in developing novel and effective therapies for this common and disabling
disorder, there is a clear need to rethink the paradigms and dogmas of this research field.
Worldwide, researchers and funding agencies have been analyzing potential causes for the
translational roadblock. Independently, several common themes have evolved from these
discussions (Table 1). One view is that the complexity of the stroke research problem cannot
be solved on a local or a national level, and that a transnational effort may be needed to
bundle preclinical research capacity and link it to the clinical realm.
Multiple Opportunities
Most experts agree that there is no fundamental reason to believe that reperfusion and
treatment in stroke units need to remain the only effective treatment options for patients with
ischemic stroke. This optimism is fueled by the observation that numerous examples of
preclinical research have parallel examples of improved outcomes in the clinic (Table 2). In
addition, opportunities are available for multidisciplinary strategies to generate new
knowledge on prevention, mechanisms of injury, plasticity, and repair. The Stroke Progress
Review Group has identified and prioritized many scientific research opportunities and
medical needs in stroke prevention, treatment, and recovery research.16
Prevention
Technological advances in high throughput genotyping will allow major breakthroughs in
the elucidation of the genetics of cerebrovascular risk factors, in particular through Genome-
Wide Association Studies46 and exome sequence analysis.47 An important focus will be the
prevention of cerebral small vessel disease, a major contributor to age-related cognitive
impairment, and a range of agents that might reduce damage to cerebral small vessels in
high-risk populations are currently undergoing preclinical testing.48
Treatment
Reperfusion via intravenous thrombolysis has helped to establish the time is brain concept in
acute stroke treatment and accomplish major improvements in treatment infrastructure,
culminating in the concept of mobile stroke units.49 These studies have paved the way for
testing hyperacute (golden hour) treatments, including some previously tested agents, which
may have been effective had they been initiated earlier than they were in prior trials. Recent
research on endogenous brain protective strategies has led to the discovery of a number of
promising treatment strategies that boost such evolutionarily conserved mechanisms.6
Although clinical beneficial neuroprotection has been elusive so far, brain protection in
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combination with reperfusion seems logical and carries the potential to increase the benefit
of reperfusion by blocking some of its deleterious effects.50 In addition, the efficacy of
recanalization and reperfusion may be improved, either by the use of alternative
thrombolytics51 or by mechanical devices.52
Recovery and Rehabilitation
The brain can recover function after injury, at least partially. Only recently we have started
to understand the mechanisms of this remarkable plasticity and regeneration. This has led to
pharmacological strategies to foster recovery, pharmacologically, via cell therapy,
rehabilitation measures, stimulation devices, or robotics.53 For example, there is strong
evidence that transcranial electric stimulation, in particular, when combined with behavioral
practice has beneficial effects on stroke rehabilitation outcomes.54 Likewise, there seem to
be exciting opportunities for neuromodulation of stroke recovery through emerging
technologies, such as MR-guided focused ultrasound. Biotechnological developments may
provide new avenues for fostering endogenous recovery, whereas nanotechnology drug
delivery approaches offer novel possibilities for stroke treatment. The remarkable advances
in cell therapy for stroke underscore the firm role of this strategy in future research
endeavors.
Further opportunities to develop successful strategies to prevent and to treat stroke
successfully are emerging from research on the interplay of the various cellular elements of
the brain, the neurovascular unit.55 In a paradigmatic shift, the field has realized that a
neurocentric view oversimplifies stroke pathophysiology. Since then it has become clear that
a complex interaction of endothelial cells, astrocytes, microglia, pericytes, inflammatory
cells from the blood, etc, determines the fate of brain tissue after stroke. This research has
now exposed numerous new targets for treatment.56
Another transformative area was the investigation of the complex interaction of the injured
brain after stroke with peripheral organs,57 in particular, the immune system.58
Complications are a highly important contributor to the morbidity and mortality of stroke,
and also a major problem for recovery.59 We are now starting to understand the underlying
mechanisms (eg, stroke-induced immunodepression), which increases susceptibility to
infection,60) and promising therapies are being developed. It is very likely that ongoing
research on the interaction of the brain after stroke with systemic metabolism, the
cardiovascular system, the liver, the gut microbiome, etc, will lead us to further therapeutic
targets to improve stroke outcome.
All these approaches will be greatly helped by the advances in the identification and
validation of biomarkers (blood, imaging61,62) for most relevant stroke subtypes in
combination with (epi)genetic and premorbidity phenotyping to predict disease
pathophysiology. The ultimate goal of these promising developments is to use
transcriptomics, proteomics, as well as immunology, and noninvasive brain imaging
(computed tomography, MR, single-photon emission computed tomography, positron
emission tomography) to establish diagnostic fingerprints of disease-specific markers to
stratify patients in a time and pathophysiological context-dependent manner.
In all these areas, we are only beginning to understand the pathobiological mechanisms, and
it is clear that further preclinical research is necessary. Agreement exists that modeling of
cerebrovascular disease should include advanced age and comorbidities typical of the human
disease, such as diabetes mellitus and hypertension, as well as environmental factors (eg,
Fisher et al63). However, because of the overwhelming costs and technical challenges of
modeling stroke in aged comorbid animals, most studies have used healthy young animals.
This could be overcome by combining the expertise and availability of models and
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confounders in a network of international experts, and by providing incentives for
crossvalidation within the network.
Thus, numerous possibilities for transnational research cooperation exist that address the
problems of fragmentation, limited resources, and the need for multidisciplinary training of
new stroke scientists.
Following the example of clinical medicine, in which multinational consortia conduct
clinical trials, and some highly effective international cooperation in the preclinical realm
(see below), we propose the development of multinational stroke research initiatives.
Sharing data and biomaterial in preclinical stroke research, as well as combining research
excellence to elucidate novel pathophysiological concepts, and consensus on therapeutic
targets, could accelerate translation to clinical trials. This could lead to the establishment of
international quality standards with crossvalidation and reproduction of results before
decision making on clinical development.64,65
Successful Examples of International Research Collaboration
Research is an international effort and scientists are already collaborating on many
individual cerebrovascular research projects. However, scaling up collaborations to the level
required to generate the resources and synergies needed requires a structured process.
Ideally, such a process can be simultaneously executed by groups of researchers and
clinicians (bottom-up) and by funding agencies and scientific societies (top-down) in a
coordinated way. An example for a successful bottom up interaction of international
scientists is the development of thrombolysis for stroke in the 1980s–2000s, which in its
course also led to an improvement in clinical stroke trial expertise. However, a top example
of a highly successful structured international research collaboration in biomedicine, is the
deciphering of the human genome. We may also learn how to organize and govern
multinational research from ongoing international collaborations, such as those in genetics.
Triggered by rapid methodological advances in genotyping large numbers of individuals,
successful approaches to project selection, data deposition and distribution, collaborative
analysis, publication and protection of intellectual property claims on a large, international
scale were recently developed (eg, GAIN Collaborative Research Group66), many of which
can serve as templates for other fields. Extreme but instructive examples from outside
medicine include research collaborations in physics that are focused on experiments using
expensive equipment (particle accelerators and detectors, eg, European Organization for
Nuclear Research CERN: http://www.cern.org) or on research on matter under extreme
conditions of temperature, pressure, or density (eg, Extreme Matter Institute EMMI: http://
www.gsi.de/emmi). Apparently, the physics community has established a culture of
collaboration that makes possible such highly successful large-scale initiatives and that
pervades their entire research operation, including their publication practice (eg, their
archive for electronic preprints of scientific papers arXiv:http://www.arxiv.org). We would
hope that stroke pathophysiology is easier to decipher than the fundamental physical laws of
nature, but we suggest that many lessons can be learned from these other examples of
international scientific cooperation, in particular, with respect to organization, upscaling,
and governance. Importantly, a strong foundation for development of international stroke
research collaborations has been laid by 2 large preclinical research consortia that are
currently demonstrating the benefits of sharing results, distributing tasks, and bundling
expertise in stroke research. These are the European Stroke Network and the Canadian
Stroke Network, which have recently initiated unique pilot collaboration across the Atlantic
(Table 3).
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Benefits and Added Value
The experience of the European and Canadian Stroke Networks has demonstrated that
multidisciplinary expertise can provide high levels of complementarity. Pooling of
resources, mutual training opportunities, and exchange of research expertise have served to
enhance and accelerate the process of translation. Complex issues can be broken down and
distributed in a coordinated fashion between partners. The vast experience of these stroke
networks suggests that further benefits could be reaped from enhancement of their
previously developed avenues of collaboration. For example,
1. Stroke research data repositories would collect data about results or planned
experimental trials and also produce a catalog of models and methods platforms
offered by participating centers to the network. In the stroke clinical trial area, such
repositories already exist, for example, at the Cochrane Stroke Group (http://
stroke.cochrane.org/) or the Virtual International Stroke Trials Archive (http://
www.vista.gla.ac.uk/.) Data contained in these repositories have already provided
answers to many clinical problems.
2. The use of common standards and data elements (such as NINDS CDEs for clinical
stroke research, http://www.commondataelements.ninds.nih.gov/Stroke.aspx)
streamlines research, and allows data sharing.
3. Sharing of biomaterials allows the most effective use of precious tissue samples
from experimental models and organisms.
In addition to these already existing forms of collaboration in the stroke field, we propose
novel forms of interaction:
1. Participating stroke researchers would consent to certain quality standards and
common end points and use similar tests to compare and share results (open labs).
This would facilitate the free movement of researchers, data sharing (including
neutral or negative findings), and exchange of protocols (including feedback/input
on methodological difficulties and solutions).
2. Laboratories might organize reciprocal audits and data monitoring, as well as
conduct round robin tests.
3. A network of experimental laboratories could organize multicenter trials to
replicate key results and perform pivotal trials, or conduct randomized phase III
type preclinical trials. These examples are neither complete nor exclusive; various
combinations are possible (eg, multicenter trial and common data elements, or
common data elements and data repositories).
4. These multicenter studies would be based on well-defined study protocols,
including robust sample size calculations, and would be of sufficient scale to
deliver the large numbers of animals required to demonstrate smaller, but possibly
more clinically relevant, treatment effects.
5. By allowing experiments with a factorial or stratified design (including different
strains and/or species, different severity of injury, different comorbidities) the
robustness of conclusions of efficacy, and their generalizability, could be increased.
67
Toward Realization of International, Multicenter Preclinical Trials
Bath et al64 and Dirnagl and Fisher65 have called for international, multicenter preclinical
phase III-type studies before moving from stroke models to clinical trials. Such phase III
preclinical trials would require international participation, thus representing structured
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international collaboration in preclinical stroke research. They are not intended to replace
basic stroke research targeted at discovering or investigating pathophysiological
mechanisms or drugs (preclinical phase I), or initial preclinical trials to demonstrate efficacy
by individual scientists (preclinical phase II). Rather, they would be based on such prior
studies, and only those compounds or treatment principles that were highly promising in
phase I and II would move into phase III. Design elements would include steering and data
monitoring committees, robust and clinically relevant outcome measures, use of biomarkers,
sufficient statistical power, prespecified primary efficacy end point, as well as hypotheses
generating secondary end points, registration in public registry (mandatory for publication in
scholarly journals). The complexities of a multicenter multimodal paradigm might indeed be
a strength of this collaborative format: the inclusion of centers with various focal cerebral
ischemia models may be considered to recreate the heterogeneity of stroke subtypes and the
varying severity of this disorder. Various strains (or even species) may be used to mimic
patient heterogeneity. Studies could be designed in such a way that they are informative
even when the results are neutral or negative. Several international stroke research consortia
are currently aiming to develop the capacity to undertake international multicenter animal
studies to improve the validity and generalizability of current preclinical research.
A variation of this format may be deduced from the clinical Neurological Emergencies
Treatment Trials Network (http://www.nett.umich.edu/nett) of the NIH/NINDS. It is based
on the idea that promising new trials of drugs for acute neurological emergencies that are
ready for phase III trials should be conducted by sites that have networks of hospitals with
active emergency departments that can run clinical trials. In a similar fashion, principal
investigators would submit an application for a phase III preclinical trial to a network of
collaborating laboratories suitably equipped to conduct high-quality efficacy trials in
animals, and the application would undergo peer review. Each site could apply to become a
center on the basis of their expertise, commitment to high-quality and rigorous standards,
and unique resources. A review or governance committee could decide on the selection of
sites on the basis of the overall aims, scope, and goals of the preclinical consortium. Positive
results that attest to robust efficacy could then be the benchmark for advancing into clinical
trials. The pharmaceutical industry could be approached to support such a network as well
and have their treatment platforms deemed appropriate for evaluation by the international
preclinical network.
Open Issues
True cooperation, as proposed here, raises a number of issues. First and foremost, the
scientific community (researchers, journal editors, scholarly societies) needs to move from
reflection (this article) to action. A bottom-up approach in which we share data and consent
on quality standards could be the beginning. In parallel, international and national funding
bodies, such as the European Commission, the NIH, the Canadian government, the
Australian National Health and Medical Research Council, the National Science Foundation
of China, etc, need to be convinced of the potential value of such collaborations.
Globalization of the scientific endeavor is presently a major charge of many of these
organizations, and there are promising signals that specific programs may be initiated in the
near future.
Other challenges include intellectual property management, development of structures for
mutual project governance, scientific monitoring, effective dialogue for true
multidisciplinary involvement beyond neuroscience, and delineation of the role of industrial
cooperation. Fortunately, however, previous experience in transnational networks has
provided fundamental frameworks for addressing such challenges. Another concern is
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authorship of articles generated by the international preclinical network. The example of the
physics community and how it has handled this issue is a valuable lesson.
Conclusions
Translational stroke medicine requires renewal, and international collaboration in preclinical
research may be an important step to overcome hurdles impeding progress. The tremendous
power of international research collaboration has been convincingly demonstrated in
physics, and several transnational collaborations have already delivered proof of concept in
the stroke field. The experience gleaned from such collaborations is paving the way for an
exciting new era in stroke research, which strives to harness the multitude of benefits
achievable through international collaboration. Now is the time for concrete action to
advance the agenda and establish an international preclinical stroke network.
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Table 1
Lost in Translation—Some Potential Reasons Why Clinical Stroke Trials Were Unable to Replicate Bench
Findings
Complexity of ischemic pathophysiology underestimated
Low quality of preclinical studies, underpowered, effect sizes overestimated, results not robust (low internal validity)
Stroke models do not match with patient characteristics (age, sex, comorbidities, polypharmacology; low external validity)
Negative publication bias (particularly in preclinical research)
Heterogeneity of stroke patients, therapies not matched to individual pathophysiology
Super systemic effects (on immune, cardiovascular system, etc) attributable to a substantial fraction of stroke morbidity and mortality, but little
understood and
under-researched
Timing of therapy wrong or clinically irrelevant, clinical trial design not matched to preclinical findings
Significant species differences
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Table 2
Found in Translation—Stroke Models Predict or Parallel Clinical Phenotypes
Pathophysiological concepts The penumbra concept was developed and refined in animal
models of
cerebral ischemia, and has proven clinical usefulness
Astrup et al23
Thrombolysis is the only pharmacological treatment of acute
ischemic
stroke of proven efficacy, is equally efficacious in embolic
models of
stroke
Zivin et al,24 The National Institute of
Neurological
Disorders and Stroke rtPA Stroke Study
Group25
Spreading depolarizations and spreading ischemia, first
described in
animal models, occur in humans and correlate with spread of
lesion
Dreier26
Treatments Identical time window for rtPA thromobolysis in rodents and
humans
Quartermain et al,27 Zhu et al,28 Lees et al29
Hypothermia, a concept originating from and refined in animal
models
of cerebral ischemia, has entered clinical guidelines to protect
the brain
after cardiac arrest
Rosomoff,30 hypothermia after Cardiac
Arrest Study
Group,31 Bernard et al32
In mouse and man: increased risk of hemorrhage and BBB
disruption in
erythropoietin/tPA treatment
Ehrenreich et al,33 Zechariah et al34
Mouse studies predict outcome of human GPIIb/IIIa receptor
antagonist trial
Kleinschnitz et al,35 Adams et al36
In mouse and man: statin use during stroke is protective,
withdrawal is
potentially harmful
Gertz et al,37 Flint et al38
In mouse and man: clinical deterioration after treatment with
xenogenic
intercellular adhesion molecule-1 antibody (Enlimomab)
Furuya et al39; Enlimomab Acute Stroke
Trial
Investigators40
Complications Weight loss and sarkopenia after stroke: body weight changes
after
experimental stroke parallel those in humans
Jönsson et al,41 Scherbakov et al42
Super systemic effects of stroke in animal models are predictive
for
those effects in humans (eg, immune system and infection)
Prass et al,43 Urra et al,44 Vogelgesang et
al45
BBB indicates blood brain barrier; rtPa, recombinant tissue-type plasminogen activator; and tPA, tissue-type plasminogen activator.
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Table 3
Examples of Already Existing Large-Scale/Transnational Cooperations in Preclinical Stroke and Stroke-
Related Research
European Stroke Network A
collaborative
effort of the
European
Union’s
Seventh
Framework
Program that
brings together
researchers,
government,
industry, the
nonprofit
sector, and
patient group
associations. It
coordinates
the research
efforts of 29
institutions
in 13 countries
http://www.europeanstrokenetwork.eu
Canadian Stroke Network Established
with the help
of the
Canadian
government in
1999.
It incorporates
>100
researchers at
24 universities
at present
http://www.canadianstrokenetwork.ca
InTBIR A
collaborative
effort of the
European
Commission,
the Canadian
Institutes of
Health
Research and
the National
Institutes of
Health. In July
the European
Commission
2012 issued a
call
(HEALTH.
2013.2.2.1-1)
to support
InTBIR with
≤30 Mio
http://ec.europa.eu/research/health/medicalresearch/brain-research/internationalinitiative_en.html
Transatlantic networks-Fondation Leducq Transatlantic
Networks of
Excellence in
Cardiovascular
and
Neurovascular
Research. The
program
awards grants
of up to
US $6 000 000
over 5 years to
collaborative
http://www.fondationleducq.org
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teams of
European
and North
American
scientists,
allowing
researchers to
take
advantage of
the strengths
and resources
on both sides
of the
Atlantic
SIRIUS: Sustained Investigation of
Recovery and
Immunologic response after stroke Using
neural Stem cells
The
Department of
Neurosurgery
of the Stanford
University and
the
Translational
Center for
Regenerative
Medicine
(University of
Leipzig)
collaborate to
assess safety
and efficacy
parameters of
allogeneic
stem cell
therapy for
stroke in a
large animal
species
before
entering a
clinical trial.
Supported by
national
funding
agencies (the
California
Institute for
Regenerative
Medicine and
the German
Ministry for
Education and
Research)
http://www.trm.uni-leipzig.de/en/research/sirius/research-project-sirius/r-sirius-a-1184.html
InTBIR indicates International Initiative for Traumatic Brain Injury Research.
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